DESCRIPTION:


FiteBac® K18/MMA


10% K18 formulated in liquid MMA

INDICATIONS FOR USE


Liquid MMA component for 2-part acrylate system

TARGET AUDIENCE:


Dental Laboratories

DEVELOPMENT STATUS:


Cleared for use in certain dental acrylics


PLANNED COMMERCIAL INTRODUCTION:


Q1/2019


BENEFITS:


Manufacture of dentures and retainers with long term antimicrobial resistance to biofilm formation.


DESCRIPTION:


FiteBac® Cavity Cleanser


2% K21 QAS aqueous ethanolic solution

INDICATIONS FOR USE


Intended for cleansing and moistening/re-wetting of cavity preparations

TARGET AUDIENCE:


Prescritpion use for Dental Professionals


DEVELOPMENT STATUS:


Under FDA Review

Q1/2019

PLANNED COMMERCIAL INTRODUCTION:


Q3/2019

BENEFITS:


Remove debris in carious lesion preparations and can penetrate exposed dentin tubules allowing restorative adhesives to tightly bind to the prepared dentin surface



DESCRIPTION:


FiteBac® CC Ortho-Seal


5% K18 in a dental sealant


INDICATIONS FOR USE


Sealant applied to enamel prior to placement of orthodontic bracket adhesive


TARGET AUDIENCE:


Prescription use for Dental Professionals


DEVELOPMENT STATUS:


510(k) Submission

Q2/2019

PLANNED COMMERCIAL INTRODUCTION:


Q4/2019

BENEFITS:


Resistance to biofilm formation around and under orthodontic brackets. Reduce risk of surface damage to surface enamel of teeth. Improved cosmetic outcomes.


DESCRIPTION:


FiteBac® FT Bond


5% K18 in a permanent acrylic based dental adhesive


INDICATIONS FOR USE


Permanent placement of dental appliances and restorations

TARGET AUDIENCE:


Prescription use for Dental Professionals


DEVELOPMENT STATUS:


510(k) submission

Q2/2019

PLANNED COMMERCIAL INTRODUCTION:


Q4/2019

BENEFITS:


Resistance to biofilm formation, loss of adhesion and decay under permanent dental restorations.